THE SIGNAL

Robert Duggan and Mahkam Zanganeh, the two co-CEOs of Summit Therapeutics, each bought 3,810,000 shares at $13.12 on the same day, committing $49,987,200 apiece. Combined, that is just under $100 million of personal capital deployed in a single coordinated move at the top of the company.

This is the strongest insider signal structure that exists in public markets. Two executives, equal in authority, equal in share count, equal in price, buying on the same day. The synchronized scale removes any possibility that this is a routine diversification adjustment, a 10b5-1 plan artifact, or a token show of confidence. When both co-CEOs move $50 million each on the same day, they are telling you something specific about what they see inside the building.

The supporting cast is equally notable. A 10% owner stepped into Prothena at depressed prices. The Chairman and CEO of Pebblebrook Hotel Trust bought $699,200 of his own hotel REIT. The Executive Chairman of American Assets Trust added $738,900 of a commercial real estate portfolio that public markets have been treating as collateral damage from interest rate pressure. Brazil's Santander CEO bought his own bank. Gaotu's CEO bought Chinese ed-tech. A director at Aurora Innovation, the autonomous vehicle company, added $498,300 at $6.04 per share.

The cluster spans biotech, real estate, hospitality, fintech, and emerging markets. The pattern is unusually broad.

THE INTERPRETATION

What the Summit Co-CEOs Are Seeing

As co-CEOs of a clinical-stage therapeutics company, Duggan and Zanganeh sit at the intersection of every material fact that drives Summit's valuation: trial enrollment pace, safety signal monitoring, data readout timing, partnership negotiations, regulatory correspondence, financing runway, and the internal confidence level of the clinical team. They see the actual curve of the data before any external analyst or investor does.

When two people with that combined visibility each commit $50 million of personal capital to the same stock on the same day, the forensic read is straightforward: they believe the market is pricing in a risk or an uncertainty that, from where they sit, is already resolving or is being materially overstated.

The public market prices biotech on binary risk: trial works or fails, partnership happens or doesn't, dilution arrives or doesn't. Co-CEOs who have visibility into the actual state of those variables are buying $100 million combined precisely when the market is most uncertain. That is the contradiction. The market is uncertain; the co-CEOs are not.

What they uniquely know that outsiders cannot access:

• Internal data readout timelines and the confidence of the clinical team in current trajectories
• The actual state of any partnership or licensing dialogue
• The financing situation and runway, which removes or confirms dilution risk
• The regulatory feedback loop, including any informal FDA correspondence

A $50 million personal commitment is not consistent with a co-CEO who has any serious internal doubt about at least one of those variables breaking favorably.

What the REIT and Hotel CEOs Are Seeing

Jon Bortz at Pebblebrook and Ernest Rady at American Assets Trust are buying into the sector that the public market has treated most harshly over the past two years. Commercial real estate and hotel REITs carry the double burden of rate sensitivity and recession fear. The public narrative has been that occupancy is fragile, refinancing is punishing, and terminal capitalization rates are compressing equity value.

Bortz and Rady, who between them oversee hundreds of millions of square feet of real assets and see internal occupancy reports, lease renewal data, and capital structure in real time, are buying at current prices. That is a direct contradiction of the public narrative.

What they uniquely know:

• Actual occupancy rates versus analyst models, which often lag by one to two quarters
• Lease renewal spread and tenant health at the property level
• Refinancing progress and the real cost of rolling debt in the current rate environment
• RevPAR trends at the property level for Pebblebrook, ahead of any public reporting period

When a hotel CEO buys his own stock after a sector drawdown, the most forensically defensible read is that internal RevPAR and booking data for the next quarter is running ahead of what the Street has modeled.

What the Gaotu and Santander Brasil CEOs Are Seeing

Xiangdong Chen at Gaotu and Mario Roberto Opice Leao at Santander Brasil represent two markets that carry heavy geopolitical and macro discounts in public pricing. Chinese ed-tech and Brazilian banking both get penalized well beyond their underlying operating conditions because of political headline risk.

A CEO buying their own stock in these environments is making a specific claim: the operating reality inside their company is better than the discount the market has applied for macro reasons.

For Chen, that means enrollment, monetization, and regulatory posture are better than the market's worst-case scenario for Chinese education policy. For Leao, that means credit quality, earnings momentum, and capital ratios are holding up despite whatever Brazil macro narrative is currently depressing the share price.

THE EVIDENCE

The Cluster Effect Across Sectors

Historical research on insider cluster buys consistently shows that the predictive power of insider purchases increases materially when multiple unrelated insiders in different sectors make discretionary open-market purchases within a short window. That is precisely what this filing window shows.

Across a four-day period, the following operator-insiders made discretionary purchases:

• Two biotech co-CEOs (Summit)
• A 10% owner in a beaten biotech (Prothena)
• A REIT executive chairman (American Assets)
• A hotel REIT chairman and CEO (Pebblebrook)
• A Brazilian bank CEO (Santander Brasil)
• A Chinese ed-tech CEO (Gaotu)
• An autonomous vehicle director (Aurora Innovation)
• A payments network director (Evertec)
• A shipping insider (Navios)
• A small E&P director (Infinity Natural Resources)

The breadth of that list, spanning five separate sectors across three continents, suggests that insiders across the economy are seeing the same macro undercurrent: the risk level that public markets are pricing is above the risk level that operators are actually experiencing.

The Summit Trade Structure Deserves Special Attention

The forensic detail that elevates the Summit trade above all others in this window is the structural symmetry. Both co-CEOs bought the exact same number of shares (3,810,000) at the exact same price ($13.12) for the exact same total ($49,987,200). Their resulting ownership levels are identical at 573,883,879 shares each.

That level of coordination requires a shared conviction so explicit that both executives aligned on size and timing simultaneously. In the context of a clinical-stage biotech, there is a limited universe of shared information that would produce this behavior. The most forensically consistent interpretation is that both co-CEOs have assessed the same internal data set and reached the same conclusion about valuation relative to near-term catalysts.

REIT Buys Appear Countercyclical on the Right Variable

Public sentiment on commercial real estate has been shaped by office vacancy headlines and rate-hike narratives. Both Pebblebrook and American Assets operate portfolios that include assets somewhat insulated from pure office vacancy risk. The insider buys suggest management believes the market has applied a sector-wide discount that is not warranted by their specific portfolio performance.

Historically, executive chairman and CEO buys in REIT names after sector drawdowns have been among the more reliable contrarian signals in the real estate space, because operators have direct visibility into the one variable the market consistently models with a lag: actual cash flow at the property level.

Gaotu Represents a Structural Mispricing Pattern

Chinese education stocks have been penalized since 2021 regulatory actions reshaped the sector. A CEO buying $447,000 of his own stock at $2.23 per share in June 2026 is making a claim about survivorship and recovery that no external analyst is positioned to make with the same confidence. The CEO controls the operating levers, knows the regulatory dialogue, and has a clearer view of the monetization runway than any outside observer.

THE REALITY CHECK

The aggregate message from this insider window is that operating conditions across biotech, real estate, hospitality, financial services, and emerging markets are materially less distressed than public market pricing implies.

The three most important contradictions to hold in focus:

1. Summit Therapeutics is priced like speculative risk; its co-CEOs are buying it like near-term certainty. The $100 million combined personal commitment is inconsistent with any version of internal reality where the co-CEOs have serious doubt about imminent value creation. The market is not seeing what they see.

2. Hotel and commercial real estate insiders are buying while the public narrative of sector stress continues. The CEOs and chairmen closest to actual property-level performance are disagreeing with the headline rate-and-recession discount. Internal cash flow and occupancy data, which always precede public reporting, appear to be running better than the Street expects.

3. Emerging market CEO buys in beaten sectors are signaling that macro fear is outrunning operating reality. The CEOs of a Brazilian bank and a Chinese ed-tech company are each making personal bets that their operating metrics are better than the political and macro discount assigned by external investors.

For the next three to six months, the insider behavior in this window points toward three areas where the market's fear premium is most likely to compress:

• Biotech catalysts: The Summit co-CEO trade structure is consistent with a near-term data or partnership event that insiders expect to revalue the equity materially upward.
• REIT and hospitality cash flows: Operator buys in these sectors typically precede earnings beats or improved forward guidance that contradicts the prevailing pessimism.
• Emerging market operational resilience: CEO buys in Brazil and China signal that underlying business momentum is decoupled from the political headlines that have been driving share price weakness.

Insiders are always a lens on the present, not a guarantee of the future. But when two co-CEOs commit a combined $100 million to the same trade on the same day, the oracle's job is to state the obvious: they know something the market has not priced yet, and they are willing to stake nine figures of personal capital on it.